Improving breast cancer therapy with CDK4/6 inhibitors

Clinical Breast Cancer

Volumn 14, Issue 6, 2014, Pages 379-380

  Jaganathan, Hamsa ^a   Overstreet, Karen ^a   Reed, Elizabeth ^b  

^a Solvay Advanced Polymers LLC   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PALBOCICLIB; RETINOBLASTOMA PROTEIN; PROTEIN KINASE INHIBITOR;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; DRUG RESISTANCE; EDITORIAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SYMPOSIUM; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; ENZYMOLOGY; FEMALE;

ANIMALS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS;

EID: 84910683993     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.10.001     Document Type: Editorial

References (7)

1. S.R.D. Johnston New strategies in estrogen receptor-positive breast cancer Clin Cancer Res 16 2010 1979 1987
2. P.J. Roberts, J.E. Bisi, and J.C. Strum Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy J Natl Cancer Inst 104 2012 476 487
3. C.A. Lange, and D. Yee Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer Endocr Relat Cancer 18 2011 C19 C24
4. Pfizer's Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer. Bus. Wire 2013. Available at: http://www.businesswire.com/news/home/20130410005708/en#.VAd-qPldWB4. Accessed September 23, 2014.
5. Finn RS, Crown JP, Lang I, et al. Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer. In: ACCR Annual Meeting.; 2014:CT101.
6. Clinicaltrials.gov. U.S Natl. Institutes Heal. 2014. Available at: https://clinicaltrials.gov/. Accessed August 19, 2014.
7. Patnaik A, Rosen LS, Tolaney SM, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer. In: AACR Annual Meeting.; 2014:CT232.